ResMed RMD Lease impairment

Discontinued — last reported Q3 '21

Lease impairment at other companies

LivaNovaLIVN

$224K—

Residential Care Software$2.7M—

Revenue$1.4B+10.8%

Gross profit$891.0M+16.3%

Operating income$499.8M+17.3%

Net income$398.7M+9.2%

EPS (diluted)$2.74+10.5%

Cash & equivalents$1.7B+78.0%

Total debt$1.1B+29.8%

Total equity$6.5B+17.1%

Total assets$8.8B+16.1%

Operating cash flow$554.1M-4.2%

CapEx$33.7M+61.8%

Free cash flow$520.5M-6.7%

Market cap$29.05B-22.6%

Enterprise value$28.5B-23.3%

P/E19.1×-7.7×

P/S5.3×-2.0×

Gross margin61.6%+2.8pp

Operating margin34.2%+2.1pp

Net margin27.4%+1.3pp

FCF margin31.7%+0.4pp

Return on equity25.2%-0.6pp

Debt / equity0.2×0.0×

Current ratio3×-0.4×

Reported directly by ResMed in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseImpairmentLoss.

The official record: ResMed’s 10-Q, filed April 30, 2021, on SEC EDGAR. View the filing →